Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLuciano Di StéfanoDKDheepak KanagavelSMSandrine Macé

Discussion

Loading...

Member takes

Overview

Exploratory analysis shows mass spectrometry quantifies M-protein in relapsed/refractory multiple myeloma, indicating effective monitoring beyond conventional methods.

Key Points

  • Longitudinal monitoring achieved a 92% average reduction in M-protein among relapsed/refractory multiple myeloma patients.
  • Mass spectrometry successfully identified clonotypic peptides in 95% of baseline monoclonal samples.
  • Analysis utilized serum samples from 89 relapsed/refractory multiple myeloma patients over a 3-year period.
  • Continued monitoring with mass spectrometry suggests effective disease control and long-term MRD surveillance.

Cite This Study

Stéfano et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df40https://doi.org/10.1182/blood-2025-2268
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma2025
  2. 2Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  3. 3Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study2025
  4. 4Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial2025
  5. 5Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025